/stocks — the workspaceLOADING
All PYXSSEC filings, by type → · Earnings date & implied move · Search inside filings
Pyxis Oncology, Inc. (PYXS) is a pharmaceutical preparations company. Piotroski F-Score 2/7. 2 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-02 from PYXS's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind PYXS’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from PYXS’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on PYXS plus an auto-SWOT — built from PYXS's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PYXS using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has PYXS been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
The fair-value line is PYXS’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from PYXS’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
No tracked institution reported a position in PYXS in the latest 13F round.
Total return including reinvested dividends, from PYXS’s adjusted closing prices. Past return is not a forecast and not investment advice.
No lawmaker has disclosed a trade in PYXS under the STOCK Act.
| Dupont JakobDirector | SELL | $107K | view → |
| HUMPHREY RACHELDirector | SELL | $16K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Projected from PYXS's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPYXS files or announces.
PYXS has sold off after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much PYXS moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
PYXS has traded lower after most recent earnings releases.
A more typical earnings reaction has been approximately ±9.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-13 | -5.3% |
| 2026-05-14 | -13.0% |
| 2026-03-23 | -7.5% |
| 2025-11-03 | +9.6% |
| 2025-08-14 | +15.0% |
| 2025-05-15 | +13.1% |
| 2025-03-18 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -7.8% |
| 2024-11-12 | -9.7% |